2 assets in Papillary Glioneuronal Tumor

Therapeutic assets addressing Papillary Glioneuronal Tumor, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Dabrafenib Papillary Glioneuronal Tumor	Novartis Pharmaceuticals	P4	BB (65)
Trametinib Papillary Glioneuronal Tumor	Novartis Pharmaceuticals	P4	BB (65)